Cancer Co.'s Price Target Adjusted After Reverse Stock Split
  (7/25/22)
Late clinical-stage biopharmaceutical company Cellectar Biosciences Inc. very recently underwent a one for 10 reverse stock split. ROTH Capital Partners LLC advised that it has adjusted its forward projections for the firm and adjusted its 12-month price target to $40/share. More >

Radiotherapy Co. On-Track With Two Clinical Trials
  (7/24/22)
Plus Therapeutics Inc. is developing novel radiotherapy treatments for several rare cancer targets including glioblastoma and leptomeningeal metastases. H.C. Wainwright & Co. advised in a research note that it is reiterating its Buy rating on the company as it expects that upcoming data from two key trials for the firm's RNL-based treatments could provide a major catalyst for the stock in H2/22. More >

Pro Athlete Benefits From Co.'s Wound Treatment Device
Source: Streetwise Reports  (7/22/22)
Shares of SANUWAVE Health Inc. traded 12% higher after the company reported it successfully treated legendary football player Jim McMahon Jr. with its ENERGY FIRST system. More >

Biotech Co.'s Phase 3 Trial First to Get Grant
Source: Streetwise Reports  (7/20/22)
A revenue-generating junior biotech company based in the U.K. has become the first public company to be approved for a government grant to fund most of a Phase 3 study exploring the use of psychedelics to treat alcohol use disorder. It could be a catalyst for the share price. More >

Drug Repurposing Co. Provides Opportunity for High Rewards
  (7/20/22)
Vancouver-based pharmaceutical development firm Algernon Pharmaceuticals Inc. recently reported topline data from a Phase 2a trial of ifenprodil in IPF patients with chronic cough that met its endpoint and demonstrated promising initial efficacy. Research Capital Corp. advised that it is maintaining its CA$25.00/share price target and "Speculative Buy" rating on the company. More >

Trial Results Show New Drug Improves Dry Eye Symptoms
Source: Matthew Caufield   (7/19/22)
These study data from Aldeyra Therapeutics Inc. solidified the therapeutic's path to filing a new drug application, potentially in Q3/22, noted an H.C. Wainwright & Co. report. More >

Biopharma Co. Looks to Expand New Drug Label Down the Road
  (7/18/22)
ScPharmaceuticals Inc. just released topline results from a Phase 2 pilot study supporting the drug developer that is pursuing the expansion of its new drug label, noted an H.C. Wainwright & Co. report. More >

Healthcare Co.’s Psychedelic-Assisted Treatments Have ‘Blockbuster Drug Potential’
Source: Patrick Trucchio  (7/15/22)
Psychedelic-assisted therapy has shown in a clinical trial that it can help patients with alcohol use disorder (AUD) or alcoholism. One company hopes to bring its treatments to clinics throughout Europe and become the go-to standard of care for AUD. More >

Pharma Co. Reduces Mortality Rates by 70% in ALS Trial
Source: Streetwise Reports  (7/15/22)
Shares of Clene Inc. traded 38% higher yesterday after the company reported that its CNM-Au8 was shown to significantly decrease mortality in its RESCUE-ALS long-term extension trial. More >

Biopharma Co. Posts 17% BMI Reduction in Ph. 2 Trial
Source: Streetwise Reports  (7/14/22)
Shares of Rhythm Pharmaceuticals Inc. rose by over 30% after the company posted positive interim results from its Phase 2 clinical study of setmelanotide in hypothalamic obesity. The data shows that after 16 weeks of treatment with setmelanotide, patients experienced a 17.2% mean reduction in BMI and a mean weight loss of 15.8%. More >

Three Analysts Like Healthcare Co.'s Upside
Source: Streetwise Reports  (7/11/22)
It is difficult to get three people to agree on anything, let alone three investment analysts. But that is precisely the case with one junior biotech company that has shown in a clinical trial that its ketamine-assisted therapy for alcohol use disorder (AUD) is three times more effective than the current standard of care. More >

Pharma Looks To Improve Potential Psychedelic Stroke Drug
Source: Streetwise Reports  (7/11/22)
Can a psychedelic compound help you heal after a stroke? This biopharmaceutical company hopes it can and plans to start Phase 1 trials this September. More >

New Drug Is Shown to Help Stopped or Reduced Bile Flow
  (7/10/22)
Albireo Pharma Inc.'s positive Phase 3 trial results indicate the medication would afford patients clinical and quality of life benefits, noted an H.C. Wainwright & Co. report. More >

New DMD Drug Yields 'Compelling' Data
  (7/9/22)
A statistical reanalysis of trial results from Sarepta Therapeutics Inc. shows improved patient function, noted an Oppenheimer report. More >

Amended Agreement to Benefit Two Biotech Firms
  (7/8/22)
In the new arrangement between Beam Therapeutics Inc. and Verve Therapeutics Inc. each of the companies grants the other an exclusive license, one to a base editing target, the other to a gene delivery technology, noted a Wedbush report. More >

Co. Makes Financing Deals Around Two of Its Approved Drugs
  (7/7/22)
The agreements include milestone payments based on future revenue from sales of the biopharma Blueprint Medicines Corp.'s therapies, noted a Wedbush report. More >

Strong Data Suggest FDA Will Approve New Lymphoma Drug
  (7/6/22)
A green light is expected for the treatment after its developers submit a biologics license application for it, planned for H2/22, noted an H.C. Wainwright & Co. report. More >

The FDA Is Expected to Approve New Narcolepsy Drug
  (7/5/22)
Avadel Pharmaceuticals Plc., the biopharma company behind this treatment, is currently undervalued and rated Outperform, noted an Oppenheimer report. More >

Trial of New Alzheimer's Drug Slated for Early 2023
  (7/1/22)
The biotech behind this product candidate differentiates itself from competitors with its approach to developing selective antibody therapies, noted an Argus Research Co. report. More >

Chen's Top Picks for Q3
Source: Streetwise Reports  (6/30/22)
Need to know where to go in these turbulent times? Asset manager Chen Lin has some ideas with his top picks for the third quarter. More >

BioNTech and Pfizer Secure $3.2B Vaccine Order from US Govt.
Source: Streetwise Reports  (6/30/22)
Shares of BioNTech SE traded 5% higher after the company together with its partner Pfizer Inc. reported that the two firms have agreed to provide 105 million 30 µg, 10 µg and 3 µg new doses of the SARS-Co-V2 vaccine to the U.S. government in a contract valued at $3.2 billion. The agreement includes a provision allowing the U.S. government to purchase up to an additional 195 million doses, which if exercised would increase the grand total to 300 million doses. More >

New Alzheimer's Drug Shows Promise as Monotherapy
  (6/29/22)
Athira Pharma Inc.'s treatment with this small molecule alone resulted in improvements related to both primary and secondary endpoints, indicating pharmacological activity, noted a BTIG report. More >

Dental & Animal Health Supplier Posts 10% Yearly Sales Gains
Source: Streetwise Reports  (6/29/22)
Shares of Patterson Companies Inc. traded 11% higher after the dental supply and animal health products distributor reported Q4/22 and FY/22 financial results highlighting a 9.9% increase in annual sales and an expansion in operating margins. More >

Small Cap Joins With Japan Pharma to Advance Next Generation Cancer Treatment
Source: Streetwise Reports  (6/28/22)
Shares of Sutro Biopharma Inc. traded 21% higher after the company announced it entered into a global collaboration agreement with Japan's Astellas Pharma to advance three novel immunostimulatory antibody-drug conjugates. More >

Approval Likely of New Gel for Skin Condition, Analyst Says
  (6/27/22)
The biotech developer of this gene therapy is preparing to launch it commercially in the U.S. and pursuing approval of it elsewhere in the world, noted an H.C. Wainwright & Co. report. More >